This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Can Pacira (PCRX) Climb 27.68% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 27.7% upside potential for Pacira (PCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Will Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Pacira (PCRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marinus Pharmaceuticals (MRNS) Stock Jumps 8.4%: Will It Continue to Soar?
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Pacira (PCRX) Down 6% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
by Zacks Equity Research
The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall
by Zacks Equity Research
Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.
Pacira (PCRX) Matches Q4 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 0% and 1.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging -17.19% in 4 Weeks, Here's Why the Trend Might Reverse for Pacira (PCRX)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Pacira (PCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 Reasons Growth Investors Will Love Pacira (PCRX)
by Zacks Equity Research
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.
Pacira (PCRX) Loses -17.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Pacira (PCRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
by Zacks Equity Research
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
All You Need to Know About Pacira (PCRX) Rating Upgrade to Buy
by Zacks Equity Research
Pacira (PCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Pacira (PCRX) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Pacira (PCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?
by Zacks Equity Research
Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
Pacira (PCRX) Lags Q3 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -12.33% and 0.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
VAXART, INC. (VXRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira (PCRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal
by Zacks Equity Research
Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
by Zacks Equity Research
The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.
Pacira (PCRX) Up on Data From Exparel Label Expansion Study
by Zacks Equity Research
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.
Why Is Pacira (PCRX) Down 9.2% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.